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Low FAS/CD95 Expression by CTCL Correlates with
Reduced Sensitivity to Apoptosis that Can Be
Restored by FAS Upregulation
Jianqiang Wu1, Minakshi Nihal1, Jawed Siddiqui1, Eric C. Vonderheid2,3 and Gary S. Wood1
FAS expression was generally low in 30 of 31 cutaneous T-cell lymphoma (CTCL) cases (mycosis fungoides/
Sezary syndrome, SS) as well as in 5 of 6 large plaque parapsoriasis cases (a CTCL precursor). To investigate this
phenomenon, we explored FAS transcript levels, cell-surface FAS protein expression and susceptibility to FAS-
mediated apoptosis in four CTCL lines (MyLa, HH, SZ4, and SeAx), freshly isolated leukemic cells from a patient
with SS, an acute lymphoblastic leukemia T-cell line (Jurkat), and JFL (a FAS-low variant of Jurkat). Results
confirmed low FAS expression by the leukemic SS cells, HH, SZ4, SeAx, and JFL relative to normal peripheral
blood mononuclear leukocytes and the other cell lines. There was a direct correlation among FAS transcript
level, FAS protein level, and FAS-mediated apoptotic sensitivity in the CTCL samples. When the FAS-deficient
cell lines were transfected with a wild-type FAS construct, FAS expression and sensitivity to FAS-mediated
apoptosis were restored. In aggregate, these findings provide evidence that like normal T cells, CTCL cells
exhibit a mechanistic connection between transcriptional regulation of FAS and sensitivity to FAS-mediated
apoptosis, point to the development of FAS deficiency as one molecular mechanism responsible for acquired
resistance to apoptosis in CTCL, and indicate that upregulation of FAS expression can restore sensitivity to
apoptosis.
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INTRODUCTION
The term CTCL refers to a biologically and clinically
heterogeneous group of T-cell neoplasms of the ‘‘skin-
associated lymphoid tissue’’ that is composed of a subset of
peripheral T cells that circulate between the skin and draining
lymph nodes through the blood and lymphatics (Wood,
2001). The mycosis fungoides (MF) variant of CTCL typically
presents with early skin lesions (flat patches and thin plaques)
that have an indolent clinical course. Later there is
progression to more clinically aggressive thick plaques and
cutaneous tumors. A leukemic variant of CTCL, known as the
Sezary syndrome (SS), also exists and is characterized by total
body erythroderma. In this study, we use the term CTCL to
refer specifically to MF/SS.
There are several lines of evidence suggesting that the
pathogenesis of CTCL depends initially on resistance to
apoptosis rather than enhanced proliferation to account for
the accumulation of tumor cells. Early CTCL begins as flat
patches or thin plaques rather than bulky tumors (Wood,
2001). The clinical pace of the disease often remains indolent
until patients evolve from the patch/plaque to the tumor
phase. Survival correlates highly with TNMB stage—both T
stage of skin lesions and overall clinical stage. Early CTCL is a
well-differentiated T-cell lymphoma composed of mature
CD4þCD45ROþ memory skin-associated lymphoid tissue
T cells (Girardi et al., 2004). Similar to normal skin-associated
lymphoid tissue T cells, early CTCL tumor cells retain the
functional capacity to home to sites of cutaneous allergic
reactions (Veelken et al., 1996). Early CTCL tumor cells
typically exhibit a low proliferative rate as assessed by mitotic
index and Mib-1/Ki-67 staining. As patients undergo tumor
progression, the mitotic index and proportion of Mib-1/Ki-
67þ cells increase (Dummer et al., 1995; Marrogi et al.,
1999). In addition to their lack of proliferation, CTCL tumor
cells also appear resistant to apoptosis. Loss of death
receptors such as FAS and tumor necrosis factor-R1
associated with blockade of death receptor-mediated
pathways was reported among CTCL cell lines (Braun et al.,
2007). In CTCL skin lesions, only very rare apoptotic
tumor cells were detected by TUNEL assay (Nevala et al.,
2001). Consistent with its low proliferative rate and
resistance to apoptosis, early CTCL is resistant to chemo-
therapy that targets rapidly dividing tumor cells (Kuzel et al.,
2003).
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In at least some cases of CTCL, there is evidence that
defective apoptotic function is due to abnormalities of FAS.
This molecule has a central role in T-cell apoptosis by
functioning as a major cell-surface death receptor. FAS is
expressed relatively strongly by cultured T cells and activated
CD45ROþ memory T cells (Li et al., 1999), which is the
subset from which CTCL is derived. Nevertheless, FAS
protein expression by CTCL has been reported to be variable
and frequently weak or negative by several investigators
using a variety of immunohistological and flow cytometric
techniques (Debusscher and Simonart, 2001; Osella-Abate
et al., 2001; Dereure et al., 2002; Contassot et al., 2008). In
another report, 8 of 12 tumor-stage MF cases and intraepi-
dermal tumor cells in 4 of 15 patch/plaque MF cases were
FAS. When serial specimens were available for analysis,
progression from early to advanced MF was associated with
loss of detectable FAS protein in 3 of 4 cases (Zoi-Toli et al.,
2000). Reduced or absent FAS protein expression was also
noted in the majority of infant acute lymphoblastic leuke-
mias, tumor-stage MF, and cutaneous CD30 non-MF large
T-cell lymphoma cases (Debusscher and Simonart, 2001; van
Doorn et al., 2002; Wood et al., 2003). In contrast, the
majority of benign T cells in cutaneous T-cell pseudolym-
phomas were FASþ in 8 of 8 cases (Debusscher and
Simonart, 2001). Among peripheral blood tumor cells from
MF or SS cases, cell-surface FAS protein expression was
highly variable. One study showed 4 of 9 FAS ligand (FAS-L)-
resistant SS cases to have deficient FAS expression relative to
normal blood lymphocytes (Contassot et al., 2008). Another
study also documented FAS leukemic cells and showed that
they were resistant to extracorporeal photopheresis, a therapy
known to induce apoptosis in T cells (Osella-Abate et al.,
2001). In contrast, FASþ cases responded to this treatment.
In aggregate, these findings suggest a role for defective
apoptosis involving the FAS pathway in the pathogenesis of at
least a subset of CTCL cases. Consequently, we assessed FAS
expression by tumor cells in samples of MF, SS, and CTCL
cell lines and found it frequently to be low relative to other
types of T cells. To further explore FAS expression in CTCL,
we used various T-cell lines to study the relationships among
FAS transcription, FAS protein expression, and sensitivity to
FAS-mediated apoptosis. Our findings are consistent with
transcriptional regulation of FAS expression in CTCL and with
a direct relationship between expression level and sensitivity
to apoptosis. Furthermore, we show that upregulation of FAS
expression restores sensitivity to apoptosis in FAS-deficient
T-cell lines including CTCL. These findings provide an
enhanced understanding of FAS expression in CTCL and a
rational basis for therapies aimed at increasing tumor cell
expression of cell-surface FAS.
RESULTS
CTCL infiltrates generally exhibit only weak FAS expression as
detected in situ by immunohistology
As shown in Table 1 and Figure 1, T cells in skin biopsy
specimens from 31 patients with CTCL and large plaque
parapsoriasis (a CTCL precursor) were generally no more than
weakly FASþ compared with autologous epidermal kerati-
nocytes and reactive T cells in lesional skin biopsies of 15
inflammatory skin diseases (chronic spongiotic dermatitis,
lichenoid drug reactions, and Jessner’s lymphocytic infil-
trate). Scattered more strongly FASþ T cells were observed
focally in CTCL and appeared to be tumor-infiltrating
lymphocytes based on analysis of semi-serial sections stained
with anti-CD8 mAb specific for the cytolytic T-cell subset. In
all cases, the CTCL tumor cells were CD4þ .
Table 1. FAS expression in situ by CTCL is generally
weak
Diagnosis Negative/Weak FAS Moderate/Strong FAS
CTCL 24 (15 patch/plaque
MF, 5 tumor MF, 2
erythrodermic MF, 2
SS)
1 (tumor MF,
heterogeneous staining)
Large plaque
parapsoriasis
(essentially early
patch-stage CTCL)
5 1
Chronic dermatoses 0 15 (8 spongiotic dermatitis,
4 benign alopecia
mucinosa, 1 Jessner’s
infiltrate, 1 lichenoid drug
dermatitis, 1 lymphomatoid
papulosis)
CTCL, cutaneous T-cell lymphoma; MF, mycosis fungoides; SS, sezary
syndrome.
Acetone-fixed frozen sections were stained with a three-stage immuno-
peroxidase method (monoclonal antibody/biotinylated goat anti-mouse
IgG/avidin-HRP) with 3,3-diaminobenzidine chromagen enhanced by
copper sulfate and counterstained with methylene blue. Two anti-FAS
monoclonals were used separately (APO-1-1 from Alexis and DX2 from
Dako). The strongest staining was recorded. Keratinocytes served as an
internal positive control. Isotype-matched IgG1 monoclonals of irrelevant
specificity served as negative controls.
a b c d
Figure 1. FAS expression in situ by CTCL is generally weak. Immunoperoxidase-stained frozen sections showing negative/weak FAS expression by CTCL tumor
cells (large arrows) in dermis (a) and epidermis (b). CTCL tumor cell clusters within epidermis (Pautrier’s microabscesses) are shown in b (large arrows). This
contrasts with much stronger FAS expression by benign T cells (stars) in dermatitis (c, d) and keratinocytes in epidermis and hair follicles (small arrows) (a–c).
Methylene blue counterstain. (a, c) Original magnification 200. (b, d) Original magnification  400. Bar¼ 100 mm in (a) and (c), and 50 mm in (b) and (d).
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Interestingly, one CTCL case had concurrent lymphoma-
toid papulosis lesions. This is a clonal T-cell lymphoproli-
ferative disorder rich in CD30þ T cells. Skin lesions undergo
spontaneous regression accompanied by lymphoid apoptosis.
The cells in the lymphomatoid papulosis lesions were
distinctly FASþ , in contrast to the nonregressing CTCL
lesions containing cells that were FAS/weak. Thus, we have
a correlation between a clinical/functional property (sponta-
neous regression by apoptosis) and FAS phenotype. The
occurrence of these distinct diseases in the same patient
controls for several confounding variables, and further
suggests the potential importance of apoptotic pathways in
CTCL pathogenesis.
CTCL cell lines and leukemic blood generally exhibit low levels
of cell-surface FAS expression
Flow cytometric analysis of four CTCL cell lines (HH, SZ4,
SeAx, and MyLa) and seven leukemic CTCL (SS) blood
samples demonstrated generally low mean fluorescence
intensity of FAS expression except for MyLa cells that were
about 10-fold higher (Figure 2). Also analyzed for FAS were
pooled normal peripheral blood mononuclear cell, Jurkat
(acute lymphoblastic T-cell leukemia line), and JFL (a Jurkat
variant with very low FAS expression). As a control to rule out
structurally abnormal FAS protein, nucleotide sequence
analysis of the CTCL lines revealed no coding region
mutations that would create defective FAS proteins that
might be expressed but undetectable by flow cytometry. One
of the seven SS patients (SS25) had both skin and blood
samples studied by immunohistology and flow cytometry,
respectively. CTCL cells in both tissue compartments
exhibited only low-level FAS expression, suggesting that this
was a general feature of this patient’s tumor cells rather than a
microenvironmentally specific phenomenon. An eighth SS
patient also showed low FAS expression by immunohistolo-
gical analysis of tumor cells in lesional skin. Overall, T cells
in 22 of 23 MF, 8 of 8 SS (7 studied by flow cytometry and 1
studied by immunohistology), 5 of 6 large plaque parapsor-
iasis, HH, SZ4, SeAx, and JFL were low in FAS compared to
moderate/high levels of FAS expressed by T cells in 15 of 15
inflammatory dermatoses, normal blood, Jurkat, and MyLa.
CTCL cell lines have levels of FAS transcript that parallel levels
of FAS protein
We used Northern blotting and real-time RT-PCR (Figure 3) to
determine FAS mRNA levels in four CTCL lines: HH, SZ4,
SeAx, and MyLa. The results show that FAS transcript level
parallels FAS protein expression with HH, SZ4, and SeAx
expressing much less mRNA than MyLa. This suggests that
reduced FAS protein expression in CTCL reflects reduced FAS
mRNA. This relationship is consistent with repeated evidence
in the literature indicating that FAS protein is transcriptionally
regulated.
Fresh mononuclear leukocytes were isolated from one SS
case (SS25) with approximately 60,000 leukemic cells per
mm3. Both FAS transcript and protein levels were low as
assessed by real-time RT-PCR and flow cytometry, respec-
tively (Figures 2 and 3). These results resemble our findings
among various CTCL lines and suggest that parallels exist
between FAS mRNA and protein levels as a general feature of
CTCL.
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Figure 2. Flow cytometry: FAS expression varies widely among CTCL cell
lines and SS blood samples. MyLa, SeAx, SZ4, and HH are CTCL lines.
SS25–31 are leukemic CTCL cells from patients with Sezary syndrome. JFL is a
Jurkat variant with almost no FAS. Blood is normal PBMC pooled from three
donors. Mean fluorescence intensity (MFI) is on y axis. Results are the mean of
triplicate analyses±SD. *Po0.05 relative to other samples.
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Figure 3. Northern blot and real-time RT-PCR analysis of FAS mRNA level in
CTCL cell lines. (a) For Northern blotting, total RNA of each cell line was
electrophoresed and transferred to nylon membrane, hybridized with biotin-
labeled FAS DNA probe or control GAPDH probe, and chemiluminescent
signals were detected. The histogram is representative of three blots and
shows densities of the FAS blot normalized to GADPH loading control. FAS
probe is designed at FAS death domain region of FAS gene (accession
number: NM_000043) from nt 1102 to nt 1584. Biotin labeling and
chemiluminescent detection kits were from Pierce. (b) For real-time RT-PCR,
cDNA was synthesized from total RNA of each CTCL cell line (MyLa, SeAx,
SZ4, and HH) and SS25 leukemic blood with SuperScript Reverse
Transcriptase and Random Primers (Invitrogen). In total, 40 cycles of real-time
PCR were performed with SYBR Ex Taq Kit (Takara Biotechnology) and primer
set: forward, 50-TGCCAAGAAGGGAAGGAGTA0; reverse, 50-
CGGGTGCAGTTTATTTCCAC0 on ABI PRISM 7000 Sequence Detection
System. Data analysis: the relative expression level of FAS mRNA of each cell
line was determined by ABI PRISM SDS software and comparative Ct method
analysis. The histogram represents three independent real-time PCR results.
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FAS function parallels cell-surface FAS protein level
To directly determine the relationship between FAS protein
expression and functional sensitivity of CTCL lines to FAS-
mediated apoptosis, we incubated CTCL lines and leukemic
CTCL cells (each with different levels of cell-surface FAS) for
16 hours with recombinant FAS-L/FLAG aggregated with anti-
FLAG mAb. Aggregation enhances trimerization of cell-
surface FAS and the resultant apoptotic signal (Huang et al.,
1999). Flow cytometric analysis of apoptosis using Annexin V
and propidium iodide showed that sensitivity to apoptosis
was roughly proportional to FAS expression. The FAS-low
samples (JFL; CTCL lines HH, SZ4, and SeAx; as well as
leukemic CTCL cells, SS25) were much more resistant to
apoptosis than the FAS-high CTCL line, MyLa (see Figure 4;
*denotes Po0.01 for MyLa compared to others). Thus, there
is a consistent relationship within these CTCL specimens: FAS
transcript levels correlate with FAS cell-surface protein levels
that correlate with FAS function (sensitivity to apoptosis).
Reduced sensitivity to FAS-mediated apoptosis can be restored
by upregulation of FAS
Our immunophenotypic studies showed that low FAS
expression is common in CTCL. Our cell line studies showed
that low FAS expression results in resistance to FAS-L-
induced apoptosis in CTCL and other types of T cells.
Therefore, we were interested to determine whether upregu-
lation of FAS expression would restore sensitivity to apoptotic
signals triggered through the FAS pathway. We transfected
FAS-low cell lines JFL, HH, SZ4, and SeAx with plasmids
containing green fluorescent protein (GFP) and FAS. The GFP
served as a control for effective transfection. Figure 5 shows
that the transfections resulted in the expected upregulation of
GFP and FAS. As also demonstrated in Figure 5, transfection
of cell lines JFL (a FAS-low variant of Jurkat) as well as HH,
SZ4, and SeAx (FAS-low variants of CTCL) with the FAS-GFP
construct did in fact restore sensitivity to apoptosis mediated
by FAS-L. For JFL, there was a 22-fold increase in apoptosis
among transfected cells treated with aggregated FAS-L
relative to untransfected cells treated similarly. For SeAx,
SZ4, and HH the differences were 13-, 6-, and 6-fold,
respectively (Figure 5, right upper quadrant values in row 3
versus row 5). Of interest, even in transfected cells not treated
with aggregated FAS-L, there was a variable increase in
spontaneous apoptosis relative to untransfected cells that was
less than twofold for SZ4 and SeAx, threefold for HH, and
sixfold for JFL (Figure 5, right upper quadrant values in row 2
versus row 4). This effect was not due to high baseline levels
of FAS-L expression because all cell lines tested showed only
low-level FAS-L on the cell surface (Figure 6). However, FAS
upregulation following transfection did result in a modest
parallel increase in FAS-L expression (Figure 7) that together
might account for the augmented spontaneous apoptosis
observed in transfectants.
DISCUSSION
This study demonstrates wide variability of FAS protein
expression in CTCL. There was more than 10-fold difference
in cell-surface FAS expression among CTCL specimens as
assessed by flow cytometry. Compared to normal blood
mononuclear leukocytes, many CTCL samples demonstrated
very low FAS levels. These results are consistent with our own
immunohistological findings reported here (Table 1) as well
as the literature showing variable expression of FAS by CTCL
cells in the skin and blood, as detected by immunohistology
or flow cytometry, respectively (see ‘Introduction’ for
references).
The literature indicates that FAS expression is transcrip-
tionally regulated in normal T cells. Our current findings are
consistent with a similar mechanism of FAS regulation in
CTCL and other T-cell neoplasms. Levels of FAS mRNA
detected by either northern blotting or real-time RT-PCR
paralleled the levels of FAS protein. Similarly, there was also
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Figure 4. Induction of apoptosis by FAS ligand in CTCL. CTCL lines (MyLa, HH, SZ4, and SeAx) and leukemic CTCL cells (SS25) were studied. Cells were plated
at 0.5 105ml1 in 2ml growth medium in triplicate wells, treated with 50 ngml1 of FAS-L/FLAG aggregated with anti-FLAG mAb for 16 hours. Apoptosis
was determined by flow cytometry using Annexin V–FITC and propidium iodide. *Po0.05 relative to other samples.
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a parallel relationship between FAS protein levels and
sensitivity to apoptosis mediated by aggregated FAS-ligand
(FAS-L). Those CTCL specimens with the greatest expression
of cell-surface FAS protein were the most susceptible to
apoptosis. Although there are minimal published data
correlating relative FAS levels in CTCL with sensitivity to
FAS-mediated apoptosis, at least one other study showed an
overall relationship between low FAS and resistance to
apoptosis in SS (Meech et al., 2001). However, another study
found that sensitivity to FAS-mediated apoptosis among
neoplastic T-cell lines did not consistently parallel levels of
FAS expression (Ni et al., 2005). Differences from our results
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Figure 5. FAS transfection restores sensitivity to FAS-L-induced apoptosis in FAS-deficient CTCL lines (HH, SZ4, and SeAx) and JFL (a low-FAS variant of
Jurkat). Row 1 (top): HH, SZ4, SeAx, and JFL cells transfected with pEF-GFP-FAS and control vector pEF-GFP show the expected upregulation of GFP and FAS.
Cell-surface FAS was detected by flow cytometry using anti-FAS-PE mAb. Murine isotype-matched antibody conjugated to PE was the negative control. GFP
signal was also detected before and after transfection. White bars show untransfected cells, gray bars show control vector-transfected cells, and black bar show
FAS vector-transfected cells. Histograms are the average of three experiments. Four lower rows: Apoptosis was induced with FAS-L/FLAG aggregated with anti-
FLAG. Apoptosis was measured by flow cytometry using PE–Annexin V and PI staining. Row 2: non-transfected cells; no treatment. Row 3: non-transfected cells;
aggregated FAS-L/FLAG treatment. Row 4: FAS-transfected cells; no treatment. Row 5: FAS-transfected cells; aggregated FAS-L/FLAG treatment. FAS-low cells
are insensitive to FAS-L (rows 2 versus 3). FAS-transfected cells are highly sensitive to FAS-L (rows 4 versus 5).
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may be due to technical variations in the apoptotic assays
used and/or the nature of the cell lines tested, some of which
were HTLV-1þ in this study.
In aggregate, the current findings support a mechanistic
linkage in CTCL between transcriptional regulation of FAS
protein expression and sensitivity to apoptosis. Our findings
indicate that CTCL cases low in FAS are resistant to apoptosis
induced by FAS-L. Because this is a major pathway for
apoptosis in T cells generally, it is likely that CTCL cells low
in FAS have a survival advantage and will exhibit resistance
to treatments that work by inducing apoptosis through FAS
signaling. In fact, this has been observed in leukemic CTCL
patients undergoing extracorporeal photopheresis (Osella-
Abate et al., 2001). In the future, assessment of FAS protein
levels could be used to define subsets of CTCL that might
prove useful for prognostication and predicting response to
specific therapies. The relatively strong expression of FAS and
CD25 by MyLa indicates that it is probably not representative
of MF/SS in general. Nevertheless, it remains useful as a
positive control for studies correlating FAS expression with
sensitivity to apoptosis.
On the basis of our findings, the low FAS protein
expression seen in many CTCL cases appears to be due to
low levels of FAS transcripts. Intracellular trapping of FAS
protein before it can be expressed on the cell surface is
unlikely because FAS mRNA levels parallel FAS cell-surface
protein levels. Furthermore, our immunohistological studies
would have identified cytoplasmic as well as cell-surface FAS
protein. Nevertheless, it is unknown why FAS is reduced in
CTCL relative to normal blood T cells and lesional T cells in
dermatitis. Possibilities involving reduced transcription in-
clude promoter abnormalities such as decreased enhancer
function and/or increased transcriptional repressor activity.
Other possibilities include decreased transcript stability or
increased transcript catabolism. These potential mechanisms
are the subject of ongoing studies.
Earlier experiments at the protein level have suggested that
CTCL cells are defective in apoptosis mediated through the
FAS pathway because of defective signaling through the T-
cell receptor/CD3 complex that results in inadequate levels of
IL-2, FAS, and FAS-L (Meech et al., 2001; Ni et al., 2005).This
proposal awaits further confirmation; however, treatment of
circulating SS tumor cells with IL-2 plus the partial protein
kinase C agonist, bryostatin-1, did increase the expression of
both FAS and FAS-L, as well as apoptosis in response to FAS
ligation (Meech et al., 2001). Interestingly, our current data
show that FAS upregulation through transfection also results
in some FAS-L upregulation. These parallel changes in FAS
and FAS-L in response to both bryostatin-1 and FAS
transfection suggest the possibility that their regulation may
be coordinated. In preliminary studies, we have shown that
the green tea polyphenol, (-)-epigallocatechin-3-gallate, and
IFN-a can cause reproducible increases in FAS expression by
at least some CTCL cell lines (Nihal and Wood, 2007) A
similar induction of FAS expression in CTCL by both IFN-a
and -g has been noted by others as well (Contassot et al.,
2008). These findings suggest the possibility of upregulating
FAS expression in tumor cells in CTCL patients—a goal made
more intriguing by our in vitro studies showing that FAS
upregulation resulted not only in increased apoptosis in
response to FAS-L treatment but also in increased FAS-L
expression and spontaneous apoptosis.
MATERIALS AND METHODS
Cell lines and plasmids
Human CTCL lines MyLa, SeAx, and SZ4 were generous gifts from
Dr Reinhard Dummer, Dr Emmanuel Contassot, and Dr Lars French
(University of Zurich); Dr Frank Braun, Dr Jurgen Eberle, and
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Figure 6. Low baseline expression of cell-surface FAS-L by neoplastic T-cell lines. Flow cytometry using anti-FAS-L mAb (white filled curves) shows minimal
FAS-L expression compared to isotype-matched negative controls (gray filled curves).
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Dr Wolfram Sterry (Charite Medical University of Berlin); and Dr Hetty
Carraway (Johns Hopkins University) and were grown in RPMI 1640
containing 2mM L-glutamine, 1mM pyruvate, and 10% fetal bovine
serum as described earlier (Nielsen et al., 1999). CTCL line HH and
acute T-cell leukemia cell line Jurkat are from the ATCC (CRL-2105
and TIB-152), and were grown in the same medium containing 10mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid. JFL is a Jurkat
variant with very low FAS expression and was a gift from Dr Janssen
(Lettau et al., 2006). The pEF-GFP and pEF-GFP-FAS plasmids were a
generous gift from Dr Vladimir Ivanov (Columbia University, NY). The
JFL (Jurkat FAS Low) cell line was a generous gift from Dr Ottmar
Janssen (University Hospital, Schleswig-Holstein, Germany).
Lesional skin and blood specimens
All clinical samples were obtained with institutional review board
approval. All patients gave informed consent and all protocols
adhered to the Declaration of Helsinki Principles. Skin specimens
included 23 MF, 2 SS, 6 large plaque parapsoriasis, and 15 benign
inflammatory skin diseases as shown in Table 1. Blood specimens
were obtained from seven stages III–IV erythrodermic CTCL patients
with SS. All had dominant T-cell clonality in their blood detected by
PCR or Southern blot analysis of T-cell receptor gene rearrange-
ments. Circulating tumor cells consisted 83–97% of lymphocytes as
assessed by cytology (Sezary cell preparation) or T-cell receptor
V-beta subfamily immunostaining.
Statistics
Statistical analysis was performed by Student’s t-test. A P-value
o0.05 was considered statistically significant and is represented as
(*) in the figures.
Immunohistology
We used a three-stage murine mAb/biotinylated goat anti-mouse
IgG/avidin–horseradish peroxidase method applied to acetone-fixed
frozen sections to assess FAS expression by CTCL and inflammatory
skin disease controls. Two different anti-FAS mAbs were used: clone
APO-1-1 (Alexis, San Diego, CA) and clone DX2 (Dako, Carpinteria,
CA). Positive controls included epidermis, adnexal epithelium, and
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Figure 7. FAS transfection results in modest upregulation of FAS-L in FAS-deficient CTCL lines. HH, SeAx, and SZ4 cells were transfected with pEF-GFP-FAS
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endothelial cells within tissue sections. Negative controls included
isotype-matched IgG1 murine mAbs of irrelevant specificity. To help
identify cell groups, we also stained semi-serial sections for a panel
of other antibodies directed against: CD1a, 2, 3, 4, 5, 7, 8, 20, 25,
30; Mib-1; and HLA-DR.
Flow cytometry
Surface FAS expression was determined by staining cells with FITC
or phycoerythrin (PE)-conjugated anti-FAS mAb DX2 (Becton
Dickinson, San Jose, CA). Surface FAS-L was detected with anti-
FAS-L mAb NOK-1 followed by PE-conjugated goat anti-mouse IgG1
secondary antibody (both from BD Pharmingen, San Jose, CA).
Isotype-matched mAbs of irrelevant specificity were used as negative
controls. Briefly, 2 105 lymphoid cells from cultured cell lines and
fresh or banked SS blood samples were collected, washed two times
with phosphate-buffered saline, and blocked with 1:10 normal goat
serum in phosphate-buffered saline for 20minutes. Cells were
immunostained for 30minutes at room temperature, then washed
twice with phosphate-buffered saline, resuspended in FACS buffer
(2% BSA in phosphate-buffered saline), and analyzed with a LSR II
bench top flow cytometer. Data analysis was performed by FlowJo
software.
Northern blotting
Total RNA (10 mg) of each cell line was electrophoresed in a 1%
agarose formaldehyde gel and transferred to Biodyne B nylon
membranes (Pierce, Rockford, IL). The membrane was prehybridized
and then hybridized with biotin-labeled FAS or control glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) cDNA probe using
Chemiluminescent Hybridization and Detection Kit (Pierce) follow-
ing the manufacturer’s instructions. The chemiluminescent signals
were detected by exposure to Blue X-Ray film. The FAS probe is
targeted to the death domain region of the FAS gene (accession
number: NM_000043) from nt1102 to nt1584 and was labeled with
biotin using a biotin-labeling kit (Pierce).
Real time RT-PCR
cDNA was synthesized from total RNA of each cell line with
SuperScript Reverse Transcriptase and Random Primers (Invitrogen,
Carlsbad, CA). In total, 40 cycles of real-time PCR (30 seconds at 94 1C,
58 1C, and 72 1C) were performed with SYBR Ex Taq Kit (Takara
Biotechnology, Japan) using primer sets designed to amplify 110bp of
FAS cDNA and 236bp of GAPDH cDNA on the ABI Prism 7000
Sequence Detection System. Primer sequences for FAS are: forward,
50-TGCCAAGAAGGGAAGGAGTA-30; reverse, 50-CGGGTGCAGTTT
ATTTCCAC-30; and for GAPDH are: forward, 50-GAAGGTGAA
GGTCGGAGTC-30; reverse, 50-GAAGATGGTGATGGGATTTC-30.
Apoptosis assay
CTCL cells were plated at 5 104ml1 in 2ml growth medium and
incubated for 16 hours with 50 ngml1 recombinant fusion protein
of FAS-L and Flag-tag (Alexis), aggregated with 1mgml1 anti-Flag
antibody (Sigma-Aldrich, St Louis, MO). Cells were collected and
washed. The percentage of the cells undergoing apoptosis was
determined by staining cells with propidium iodide and Annexin
V–FITC (1:20; BD Pharmingen) for 15minutes in the dark, followed
by flow cytometric analysis.
Nucleotide sequencing
To screen for mutations in Fas/CD95 exon regions, we used PCR and
automated nucleotide sequencing techniques. FAS regions were
amplified using genomic DNA and/or cDNA templates. Genomic
DNA from CTCL cell lines was extracted using the standard method
of proteinase K treatment and phenol/chloroform extraction. The
following primers were used to amplify the various coding regions of
the FAS exons and for sequencing (F denotes forward primer and
R denotes reverse primer in each pair): Exon 2: W196F, 50-
GTTGCTTACTTCAGAAATCAATAA-30; W197R, 50-ACTGTAATCT
GGATGTTTTGT-30; Exon 3A: W198F, 50-ACTTCCCACCCTGTTA
CCTG-30; W199R, 50-CATCACACAATCTACATCTTCTGC-30; Exon
3B: W200F, 50-GTACACCAGACAAAGCCCTTTTTC-30; W201R, 50-
GTGTCAACATAGCACCACAGTAGG-30; Exon 4: W202F, 50-CGC
GATAACTAATAGTTTCCAA-30; W203R, 50-CTCTCAGTCAGTGTTA
CTTACTTCCCTA-30; Exon 7: W208F, 50-CTACAAGGCTGAGACCT
GAGTT-30; W209R, TTTCAAGGAAAGCTGATACCTATT-30; Exon 8:
W210F, 5-TTGTCTTTCTCTGCTTCCATT-30; W211R, 50-ATTGGCC
TATTACTCTAAAGGATG-30; Exon 9A: W212F, 50-TGCTGGAGTCA
TGACACTAAGT-30; W213R, 50-CAATGTGTCATACGCTTCTTTC-30;
Exon9B: W214F, 50-TAATTGGCATCAACTTCAT-30; W215R, 50-
GAATTTGTTGTTTTTCACTCTA-30; Exon 9C: W216F, 50-GGTTTT
CACTAATGGGAATTTCAT-30; W217R, 50-CTTCATTGACACCATT
CTTTCG-30.
Total RNA was isolated using Trizol Reagent and cDNA was
synthesized using the First-Strand Synthesis System (Invitrogen). FAS
gene fragments were amplified by PCR using high-fidelity Taq
polymerase (Invitrogen). The following primers were used for PCR
amplification and sequencing of a 335 bp FAS cDNA fragment that
includes exons 1–3 and part of exon 4: W234F, 50-ATGCTGGGC
ATCTGGACCCT-30; W235R, 50-GCCATGTCCTTCATCACACAA-30.
The following primers were used for PCR amplification
and sequencing of a 338 bp FAS cDNA fragment that includes
exons 4–6: W236F, 50-CATGGCTTAGAAGTGGAAAT-30;
W237R, 50-ATTTATTGCCACTGTTTCAGG-30. All automated se-
quencing was performed at the DNA Biotechnology Center, UW,
Madison, WI.
Cell transfection
JFL cells (1 106 per sample) were transfected with pEF-GFP-FAS
plasmid by using lipofectamine LTX following the manufacturer’s
instructions. Briefly, cells were plated in six-well plates and 2.5 mg of
plasmid and 2.5 ml of PLUS reagent were diluted in 500 ml of serum-
free media, 8 ml of lipofectamine LTX was added 5minutes later. The
DNA/lipofectamine mixture was added into cells after 25minutes of
incubation. For the HH SeAx, SZ4 cell lines, 5 106 cells were
collected and resuspended in 100 ml of Nucleofector Solution V, and
2.5 mg of plasmid was added. The mixture was transferred into an
Amaxa-certified cuvette. Program X-001 was used for electropora-
tive transfection using the Amaxa AAD-1001 Nucleofector Device
(Amaxa Inc., Gaithersburg, MD).
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